大うつ病性障害の世界市場レポート 2025年

大うつ病性障害の市場規模は、今後数年間で安定した成長が見込まれます。2029年には年間平均成長率（CAGR）3.2％で71億3,000万米ドルに成長します。予測期間の成長は、精密医療、遠隔精神療法と遠隔治療、新しい治療方法、メンタルヘルスサービスの世界の拡大に起因しています。予測期間における主な動向には、早期介入、ピアサポートとオンラインコミュニティ、全体論的アプローチ、レジリエンスと対処戦略が含まれます。

薬物乱用やアルコール乱用の増加が大うつ病性障害市場の成長を牽引すると予測されます。物質・アルコール乱用とは、アルコールを含む物質の過剰で有害な使用パターンを指し、身体的、心理的、社会的に悪影響を及ぼす可能性があります。これらの問題は、大うつ病性障害と併発することが多く、両方の状態が互いを悪化させ、身体的・精神的危害のリスクを高めます。例えば、2024年7月、米国を拠点とする保健・福祉サービス部門であるSubstance Abuse and Mental Health Services Administrationの調査によると、2023年には個人の3.1％（890万人）がオピオイドを誤用していたことが明らかになりました。さらに、12歳以上の21.8％が、最もよく使用される違法薬物であるマリファナを使用し、同年齢層の9.4％が過去1ヵ月間にニコチンを吸引しており、2022年の8.3％から増加しています。その結果、薬物乱用やアルコール乱用の増加が大うつ病性障害市場の成長に寄与しています。

不安症例の増加が大うつ病性障害市場の成長を後押しすると予想されます。不安はストレスに対する自然な反応であり、しばしば恐怖、不安、恐怖の感情をもたらし、日常的な出来事に対する持続的で過剰な心配につながります。不安は大うつ病性障害に大きく影響し、神経過敏、イライラ、睡眠障害、集中力の低下をもたらします。例えば、米国を拠点とする非営利団体である米国精神医学会は、2024年5月に、成人の43％が前年と比較して不安を感じており、2023年の37％、2022年の32％から増加していると報告しています。そのため、不安の蔓延が大うつ病性障害市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界大うつ病性障害 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の大うつ病性障害市場：成長率分析
• 世界の大うつ病性障害市場の実績：規模と成長, 2019-2024
• 世界の大うつ病性障害市場の予測：規模と成長, 2024-2029, 2034F
• 世界大うつ病性障害総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の大うつ病性障害市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心理療法
• 医薬品
• 電気けいれん療法（ECT）
• 経頭蓋磁気刺激（TMS）
• その他の治療法
• 世界の大うつ病性障害市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 身体検査
• 臨床検査
• 精神医学的評価
• 精神障害の診断と統計マニュアル（DSM-5）
• その他の診断
• 世界の大うつ病性障害市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリニック
• 病院
• その他のエンドユーザー
• 世界の大うつ病性障害市場、心理療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 認知行動療法（CBT）
• 対人関係療法（IPT）
• 弁証法的行動療法（DBT）
• 精神力動的療法
• 世界の大うつ病性障害市場、医薬品の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的セロトニン再取り込み阻害薬（SSRI）
• セロトニン・ノルエピネフリン再取り込み阻害剤（SNRI）
• 三環系抗うつ薬（TCA）
• モノアミン酸化酵素阻害剤（MAOI）
• 非定型抗うつ薬
• 世界の大うつ病性障害市場電気けいれん療法（ECT）の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 片側ECT
• 両側電気けいれん療法
• 修正ECT
• 世界の大うつ病性障害市場経頭蓋磁気刺激（TMS）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 反復経頭蓋磁気刺激（rTMS）
• 深部経頭蓋磁気刺激（dTMS）
• シータバースト刺激（TBS）
• ナビゲート脳刺激法（nTMS）
• 世界の大うつ病性障害市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 認知行動療法（CBT）
• 精神力動的療法
• 対人関係療法（IPT）
• 迷走神経刺激（VNS）
• ケタミン療法
• 明るい光療法
• サイケデリック薬物療法
• 薬物療法（抗うつ薬）

第7章 地域別・国別分析

• 世界の大うつ病性障害市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の大うつ病性障害市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 大うつ病性障害市場：競合情勢
• 大うつ病性障害市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Janssen Research And Development LLC Overview, Products and Services, Strategy and Financial Analysis
  • Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi-Aventis US LLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol Myers Squibb Co.
• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Biogen Inc.
• Otsuka Pharmaceuticals Co.Ltd.
• Forest Laboratories Inc.
• H. Lundbeck A/S
• Richter Gedeon plc
• Allergan plc
• Neurocrine Biosciences Inc.
• BlackThorn Therapeutics Inc.
• Intra-Cellular Therapies Inc.
• Axsome Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 大うつ病性障害市場2029：新たな機会を提供する国
• 大うつ病性障害市場2029：新たな機会を提供するセグメント
• 大うつ病性障害市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Major depressive disorder, often referred to as clinical depression, is a mood disorder characterized by persistent feelings of sadness and a loss of interest in daily activities. These symptoms can disrupt essential aspects of life, such as sleep, appetite, and work performance, extending beyond typical mood fluctuations and profoundly affecting a person's thoughts, emotions, behavior, and overall well-being. Managing major depressive disorder involves various medical interventions to promote an individual's emotional health.

The key treatments for major depressive disorder encompass psychotherapy, medications, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and other therapeutic approaches. Psychotherapy involves the guidance of a trained mental health professional who assists individuals or groups in addressing emotional, psychological, and behavioral challenges. The diagnosis of major depressive disorder can be made through physical examinations, laboratory tests, psychiatric evaluations, references to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and other clinical methods. These interventions and evaluations are typically administered in various healthcare settings, including hospitals, clinics, and other medical facilities.

The major depressive disorder market research report is one of a series of new reports from The Business Research Company that provides major depressive disorder market statistics, including major depressive disorder industry global market size, regional shares, competitors with a major depressive disorder market share, detailed major depressive disorder market segments, market trends and opportunities and any further data you may need to thrive in the major depressive disorder industry. This major depressive disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The major depressive disorder market size has grown steadily in recent years. It will grow from $6.12 billion in 2024 to $6.28 billion in 2025 at a compound annual growth rate (CAGR) of 2.6%. The growth in the historic period can be attributed to pharmaceutical advances, mental health awareness, psychological therapies, public health initiatives.

The major depressive disorder market size is expected to see steady growth in the next few years. It will grow to $7.13 billion in 2029 at a compound annual growth rate (CAGR) of 3.2%. The growth in the forecast period can be attributed to precision medicine, telepsychiatry and teletherapy, novel treatment modalities, global expansion of mental health services. Major trends in the forecast period include early intervention, peer support and online communities, holistic approaches, resilience and coping strategies.

The increase in cases of substance and alcohol abuse is anticipated to drive the growth of the major depressive disorder market. Substance and alcohol abuse refer to patterns of excessive and harmful use of substances, including alcohol, which can result in adverse physical, psychological, and social impacts. These issues often co-occur with major depressive disorder, with both conditions exacerbating each other and raising the risk of physical and mental harm. For example, in July 2024, a survey by the Substance Abuse and Mental Health Services Administration, a US-based health and human services department, revealed that 3.1% of individuals (8.9 million) misused opioids in 2023. Additionally, 21.8% of people aged 12 or older used marijuana, the most commonly used illicit drug, and 9.4% of individuals in the same age group vaped nicotine in the past month, an increase from 8.3% in 2022. Consequently, the rise in substance and alcohol abuse is contributing to the growth of the major depressive disorder market.

The rise in anxiety cases is expected to boost the growth of the major depressive disorder market. Anxiety is a natural response to stress, often bringing about feelings of fear, unease, and dread, and can lead to persistent and excessive worry about everyday events. Anxiety significantly affects major depressive disorder, contributing to nervousness, irritability, and difficulties with sleep and concentration. For instance, in May 2024, the American Psychiatric Association, a US-based nonprofit organization, reported that 43% of adults felt more anxious in 2024 compared to the previous year, up from 37% in 2023 and 32% in 2022. Therefore, the increasing prevalence of anxiety is driving the growth of the major depressive disorder market.

Prominent companies within the major depressive disorder market are concentrating on the development of pioneering products and obtaining regulatory approvals to gain a competitive edge. The approval of novel drugs for major depressive disorder treatment, such as VRAYLAR (cariprazine), is on the rise to address the demand for more effective and safer treatments. For instance, in December 2022, the US-based pharmaceutical company AbbVie Inc. received FDA (Food and Drug Administration) approval for VRAYLAR (cariprazine) as an adjunctive therapy alongside antidepressants for the treatment of major depressive disorder (MDD) in adults. VRAYLAR represents an innovative atypical antipsychotic medication that rebalances dopamine and serotonin levels in the brain. It stands as the first atypical antipsychotic to be approved for adjunctive major depressive disorder treatment, offering the convenience of a once-daily capsule.

In March 2022, AbbVie Inc., a US-based biopharmaceutical firm, acquired Syndesi Therapeutics SA for $130 million. This strategic acquisition is intended to bolster AbbVie Inc.'s neuroscience portfolio and expand its research and development capabilities in neuropsychiatric and neurodegenerative disorders. Syndesi Therapeutics SA, a Belgium-based biotechnology company, specializes in the development of therapeutic products for major depressive disorders and other neuropsychiatric conditions.

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research And Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co.Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon PLC, Allergan PLC, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BioLite Inc., BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Arrivo Bioventures LLC, Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the major depressive disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The major depressive disorder market consists of revenues earned by entities by providing services such as teletherapy, integrated care, cognitive behavioral therapy, interpersonal therapy, mindfulness-based therapy and residential treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The major depressive disorder market also includes sales of monoamine oxidase inhibitors, tricyclic antidepressants and mirtazapine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Major Depressive Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on major depressive disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for major depressive disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The major depressive disorder market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Psychotherapy; Medications; Electroconvulsive Therapy (ECT); Transcranial Magnetic Stimulation (TMS); Other Treatments
• 2) By Diagnosis: Physical Examinations; Laboratory Tests; Psychiatric Evaluations; Diagnostic And Statistical Manual of Mental Disorders (DSM-5); Other Diagnosis
• 3) By End-User: Clinics; Hospitals; Other End-Users
• Subsegments:
• 1) By Psychotherapy: Cognitive Behavioral Therapy (CBT); Interpersonal Therapy (IPT); Dialectical Behavior Therapy (DBT); Psychodynamic Therapy
• 2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs); Tricyclic Antidepressants (TCAs); Monoamine Oxidase Inhibitors (MAOIs); Atypical Antidepressants
• 3) Electroconvulsive Therapy (ECT): Unilateral ECT; Bilateral ECT; Modified ECT
• 4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS); Deep Transcranial Magnetic Stimulation (dTMS); Theta Burst Stimulation (TBS); Navigated Brain Stimulation (nTMS)
• 5) Other: Cognitive Behavioral Therapy (CBT); Psychodynamic Therapy; Interpersonal Therapy (IPT); Vagus Nerve Stimulation (VNS); Ketamine Therapy; Bright Light Therapy; Psychedelic-Assisted Therapy; Medication (Antidepressants)
• Companies Mentioned: Pfizer Inc.; Janssen Research And Development LLC; Merck and Co. Inc.; Novartis AG; Sanofi-Aventis US LLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Major Depressive Disorder Market Characteristics

3. Major Depressive Disorder Market Trends And Strategies

4. Major Depressive Disorder Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Major Depressive Disorder Growth Analysis And Strategic Analysis Framework

• 5.1. Global Major Depressive Disorder PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Major Depressive Disorder Market Growth Rate Analysis
• 5.4. Global Major Depressive Disorder Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Major Depressive Disorder Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Major Depressive Disorder Total Addressable Market (TAM)

6. Major Depressive Disorder Market Segmentation

• 6.1. Global Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Psychotherapy
• Medications
• Electroconvulsive Therapy (ECT)
• Transcranial Magnetic Stimulation (TMS)
• Other Treatments
• 6.2. Global Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Physical Examinations
• Laboratory Tests
• Psychiatric Evaluations
• Diagnostic And Statistical Manual of Mental Disorders (DSM-5)
• Other Diagnosis
• 6.3. Global Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Hospitals
• Other End-Users
• 6.4. Global Major Depressive Disorder Market, Sub-Segmentation Of Psychotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cognitive Behavioral Therapy (CBT)
• Interpersonal Therapy (IPT)
• Dialectical Behavior Therapy (DBT)
• Psychodynamic Therapy
• 6.5. Global Major Depressive Disorder Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
• Tricyclic Antidepressants (TCAs)
• Monoamine Oxidase Inhibitors (MAOIs)
• Atypical Antidepressants
• 6.6. Global Major Depressive Disorder Market, Sub-Segmentation Of Electroconvulsive Therapy (ECT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Unilateral ECT
• Bilateral ECT
• Modified ECT
• 6.7. Global Major Depressive Disorder Market, Sub-Segmentation Of Transcranial Magnetic Stimulation (TMS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Repetitive Transcranial Magnetic Stimulation (rTMS)
• Deep Transcranial Magnetic Stimulation (dTMS)
• Theta Burst Stimulation (TBS)
• Navigated Brain Stimulation (nTMS)
• 6.8. Global Major Depressive Disorder Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cognitive Behavioral Therapy (CBT)
• Psychodynamic Therapy
• Interpersonal Therapy (IPT)
• Vagus Nerve Stimulation (VNS)
• Ketamine Therapy
• Bright Light Therapy
• Psychedelic-Assisted Therapy
• Medication (Antidepressants)

7. Major Depressive Disorder Market Regional And Country Analysis

• 7.1. Global Major Depressive Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Major Depressive Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Major Depressive Disorder Market

• 8.1. Asia-Pacific Major Depressive Disorder Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Major Depressive Disorder Market

• 9.1. China Major Depressive Disorder Market Overview
• 9.2. China Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Major Depressive Disorder Market

• 10.1. India Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Major Depressive Disorder Market

• 11.1. Japan Major Depressive Disorder Market Overview
• 11.2. Japan Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Major Depressive Disorder Market

• 12.1. Australia Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Major Depressive Disorder Market

• 13.1. Indonesia Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Major Depressive Disorder Market

• 14.1. South Korea Major Depressive Disorder Market Overview
• 14.2. South Korea Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Major Depressive Disorder Market

• 15.1. Western Europe Major Depressive Disorder Market Overview
• 15.2. Western Europe Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Major Depressive Disorder Market

• 16.1. UK Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Major Depressive Disorder Market

• 17.1. Germany Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Major Depressive Disorder Market

• 18.1. France Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Major Depressive Disorder Market

• 19.1. Italy Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Major Depressive Disorder Market

• 20.1. Spain Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Major Depressive Disorder Market

• 21.1. Eastern Europe Major Depressive Disorder Market Overview
• 21.2. Eastern Europe Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Major Depressive Disorder Market

• 22.1. Russia Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Major Depressive Disorder Market

• 23.1. North America Major Depressive Disorder Market Overview
• 23.2. North America Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Major Depressive Disorder Market

• 24.1. USA Major Depressive Disorder Market Overview
• 24.2. USA Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Major Depressive Disorder Market

• 25.1. Canada Major Depressive Disorder Market Overview
• 25.2. Canada Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Major Depressive Disorder Market

• 26.1. South America Major Depressive Disorder Market Overview
• 26.2. South America Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Major Depressive Disorder Market

• 27.1. Brazil Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Major Depressive Disorder Market

• 28.1. Middle East Major Depressive Disorder Market Overview
• 28.2. Middle East Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Major Depressive Disorder Market

• 29.1. Africa Major Depressive Disorder Market Overview
• 29.2. Africa Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Major Depressive Disorder Market Competitive Landscape And Company Profiles

• 30.1. Major Depressive Disorder Market Competitive Landscape
• 30.2. Major Depressive Disorder Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Janssen Research And Development LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi-Aventis US LLC Overview, Products and Services, Strategy and Financial Analysis

31. Major Depressive Disorder Market Other Major And Innovative Companies

• 31.1. Bristol Myers Squibb Co.
• 31.2. AstraZeneca plc
• 31.3. GlaxoSmithKline plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Eli Lilly and Company
• 31.6. Biogen Inc.
• 31.7. Otsuka Pharmaceuticals Co.Ltd.
• 31.8. Forest Laboratories Inc.
• 31.9. H. Lundbeck A/S
• 31.10. Richter Gedeon plc
• 31.11. Allergan plc
• 31.12. Neurocrine Biosciences Inc.
• 31.13. BlackThorn Therapeutics Inc.
• 31.14. Intra-Cellular Therapies Inc.
• 31.15. Axsome Therapeutics Inc.

32. Global Major Depressive Disorder Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Major Depressive Disorder Market

34. Recent Developments In The Major Depressive Disorder Market

35. Major Depressive Disorder Market High Potential Countries, Segments and Strategies

• 35.1 Major Depressive Disorder Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Major Depressive Disorder Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Major Depressive Disorder Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer